Search results
Showing 1 to 7 of 7 results for levonorgestrel
This guideline covers assessing and managing heavy menstrual bleeding (menorrhagia). It aims to help healthcare professionals investigate the cause of heavy periods that are affecting a woman’s quality of life and to offer the right treatments, taking into account the woman’s priorities and preferences.
Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.
This quality standard covers contraception for women, including emergency contraception. It describes high-quality care in priority areas for improvement.
View quality statements for QS129Show all sections
fibroids and endometrial polyps. It also facilitates the fitting of levonorgestrel-releasing intrauterine systems (LNG-IUS).A...
Ovarian cancer: identifying and managing familial and genetic risk (NG241)
This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.
Long-acting reversible contraception: levonorgestrel 13.5 mg intrauterine delivery system (ESNM41)
This evidence summary has been replaced by the long-acting reversible contraception: implementation resource summary.
This guideline covers care for women of any age (including girls and young women under 18) who request an abortion. It aims to improve the organisation of services and make them easier for women to access. Detailed recommendations on conducting abortions at different gestational stages are also included, to ensure that women get the safest and most effective care possible.